<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01344512</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2010/36</org_study_id>
    <nct_id>NCT01344512</nct_id>
  </id_info>
  <brief_title>Population Pharmacokinetics of Anti-infectious Drugs in Children</brief_title>
  <acronym>PHARMA-A</acronym>
  <official_title>Population Pharmacokinetics Of Ceftazidime, Ciprofloxacin And Voriconazole In Paediatric Young Patients (&lt; 12 Years Old)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Pharm A project is a French national collaborative project aiming to determine the
      population pharmacokinetics of ceftazidime, ciprofloxacin, and voriconazole in paediatric
      patients aged one month to five years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The licensing process was introduced in order to ensure that medicines are safe, effective
      and of high quality. However, over 50% of children admitted to hospital in France and Europe
      will receive an unlicensed or off-label medicine. This occurs for most drugs in children less
      than 6 years of age. They represent a particularly vulnerable subgroup of the paediatric
      population.

      There are major practical and ethical issues in relation to studying medicines in paediatric
      patients aged 5 years or less.

        -  They represent only a small part of the population as compared to older children and
           adults, and the variation of specific types of diseases in this young subpopulation is
           higher than in the paediatric counterpart. There are major differences in drug
           disposition in the different age groups.

        -  There is a need for suitable methodological approaches for clinical trials

        -  There are major ethical issues It is essential, therefore, to recruit children from
           various regions in France in order to obtain a critical sample size of sufficient
           magnitude and to conduct scientific sound studies. This will be achieved by performing
           Pharm A, a population pharmacokinetic study of three different anti infectious agents
           (ceftazidime, ciprofloxacin, voriconazole) and identify covariates including
           pharmacogenetic biomarkers that explain pharmacokinetic variability.

      After parental informed consent, sampling strategy will be randomized depending on the drug
      and the age group (2 samples in patients below 2 years and 3 samples in patients from 2 to 5
      years).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Population pharmacokinetic parameters and factors explaining variability</measure>
    <time_frame>Between 2 and 4 days after the begining of the treatment</time_frame>
    <description>Population Pharmacokinetic Parameters and variability factors (Sex, Age, Genetic factors...) for ceftazidime, ciprofloxacin and voriconazole.
According to the age of participants, 2 or 3 bloods sampling will be take between 2 and 4 days after the beginning of the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Covariability factors explaining the variability (age, biological data, pharmacokinetics factors, associated treatments...)</measure>
    <time_frame>Between 2 and 4 days after the beginning of the treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">214</enrollment>
  <condition>Pediatrics</condition>
  <condition>Ceftazidime</condition>
  <condition>Ciprofloxacin</condition>
  <condition>Voriconazole</condition>
  <arm_group>
    <arm_group_label>Patients treated with Ceftazidime</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients treated with Ciprofloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients treated with Voriconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftazidime</intervention_name>
    <description>Bloods sampling on patient treated with Ceftazidime between 48 hours and 4 days after beginning of treatment.</description>
    <arm_group_label>Patients treated with Ceftazidime</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>Bloods sampling on patient treated with Ciprofloxacin between 48 hours and 4 days after beginning of treatment.</description>
    <arm_group_label>Patients treated with Ciprofloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole</intervention_name>
    <description>Bloods sampling on patient treated with Voriconazole between 48 hours and 4 days after beginning of treatment.</description>
    <arm_group_label>Patients treated with Voriconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children aged 28 days to 11 years (&lt; 12 years)

          -  Receiving one of the following drugs for therapeutic reasons : ceftazidime,
             ciprofloxacin, voriconazole

          -  Representative for the clinician, a condition requiring the use of these molecules

          -  Informed consent signed by the two parents or legal representative

          -  Child affiliated to the national social security system

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphanie Bui, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Bordeaux, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Bordeaux, Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM, Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital NEcker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2011</study_first_submitted>
  <study_first_submitted_qc>April 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2011</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Population</keyword>
  <keyword>Children</keyword>
  <keyword>Ceftazidime</keyword>
  <keyword>Ciprofloxacin</keyword>
  <keyword>Voriconazole</keyword>
  <keyword>Pediatric</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

